NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

Which of the following is a boxed warning for Cladribine (Mavenclad)?

Hyperactivity
Malignancies, teratogenicity
Weight gain
Insomnia

The correct answer is: Malignancies, teratogenicity

Cladribine (Mavenclad) is a prescription medication used to treat certain types of multiple sclerosis. A boxed warning is the FDA's strongest warning about a drug and indicates that the drug carries a significant risk of serious or life-threatening side effects. In the case of Cladribine, the boxed warning is for potential malignancies and teratogenicity (ability to cause fetal harm). This means that taking Cladribine may increase your risk of developing certain types of cancer, as well as cause harm to an unborn baby if taken during pregnancy. This is why it is important to carefully weigh the benefits and risks of taking Cladribine with your doctor. Options A, C, and D are incorrect as they are not boxed warnings for Cladribine. This medication may cause other side effects, but they are not listed as boxed warnings. These side effects should still be discussed with your doctor.